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A B S T R A C T
Purpose
Survivors of Wilms tumor (WT) are at risk for adverse health and social outcomes but risks beyond
30 years from diagnosis remain uncertain. We investigated the risks of adverse outcomes among
5-year survivors of WT, in particular, those between 30 and 50 years from diagnosis.
Patients and Methods
The British Childhood Cancer Survivor Study includes 1,441 5-year survivors ofWT.We investigated
cause-speciﬁc mortality, risk of subsequent primary neoplasms (SPNs), and, for those who com-
pleted a questionnaire, the extent of smoking and drinking, educational achievement, health status,
and health service use compared with the general population.
Results
Cumulative risk of death from all causes, excluding recurrence, increased substantially from 5.4% to
22.7% at 30 years and 50 years, respectively, after WT diagnosis—75% of excess deaths beyond
30 years from diagnosis were attributable to SPNs (50%) and cardiac diseases (25%). Digestive
cancer, most frequently bowel, accounted for 41% of excess cancers beyond 30 years.
Conclusion
Between 30 and 50 years from diagnosis, survivors of WT are at a substantially increased risk of
premature mortality, and 75% of excess deaths were accounted for by SPNs and cardiac diseases.
Radiotherapy exposure was a risk factor for both outcomes. The proportion of patients withWTwho
are exposed to radiotherapy has reduced substantially in recent decades because of initiatives such
as the SIOP WT 2001 clinical trial, which sought to reduce late effects; however, the majority of
current survivors, who are at least 30 years from diagnosis, received radiotherapy. Surveillance of
this group should focus on SPNs, in particular, bowel and breast cancers, and cardiac conditions.
J Clin Oncol 34:1772-1779. © 2016 by American Society of Clinical Oncology
INTRODUCTION
The 5-year survival rate after diagnosis with Wilms
tumor (WT) has improved to 90% as a result of
advances in anticancer therapy.1 Although WT is
increasingly curable, survivors are at risk for a range
of treatment-related, long-term adverse health and
social outcomes. Survivors of WT have increased
mortality compared with the general population2,3
and are at excess risk of developing second primary
cancers,3-6 adverse pregnancy outcomes,7-9 cardiac
disease, and renal dysfunction.10
Although a number of previous studies have
investigated the risks of adverse health and social
outcomes among survivors of WT,9,11-16 none have
had sufﬁcient follow-up to satisfactorily investigate
the risks beyond 30 years from WT diagnosis; hence,
there remains considerable uncertainty regarding the
magnitude of these risks. The main advantage of
the current study—in addition to being large scale
and population based—is that 65% of the cohort
survived for . 30 years after WT diagnosis.
The objective of this study was to investigate
the risks of adverse health and social outcomes
among 5-year survivors of WT # 50 years after
diagnosis. Speciﬁc objectives were to investigate
cause-speciﬁc late mortality; the risk of devel-
oping subsequent primary neoplasms (SPNs); the
risk of adverse pregnancy outcomes; health status;
1772 © 2016 by American Society of Clinical Oncology
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smoking and alcohol consumption, educational attainment, and
marriage status; and health services use.
PATIENTS AND METHODS
British Childhood Cancer Survivor Study
The British Childhood Cancer Survivor Study (BCCSS) is a large-
scale, population-based cohort study established to investigate adverse
health and social outcomes among such survivors. The BCCSS includes
1,441 survivors of WTwho were diagnosed at age, 15 years between 1940
and 1991 in Great Britain and who survived for $ 5 years.17 The BCCSS
cohort was ascertained through the population-based National Registry of
Childhood Tumors. Limited treatment information was obtained from
clinical records to the level of detail given in Table 1.
Ascertainment of Deaths and SPNs
Ascertainment of deaths, including the underlying cause of death,
and SPNs in the BCCSS was achieved by ﬂagging the entire cohort of
survivors of childhood cancer at the National Health Service Information
Centre. Flagging informs the BCCSS when a survivor dies or develops an
SPN by linking the population-based cohort with the national population-
based death and cancer registration systems. Conﬁrmation of all SPNs was
undertaken by writing to relevant clinician(s) to obtain all diagnostic
information, in particular, pathology reports.4 Validation of causes of
deaths was undertaken by two clinicians (E.S. and G.L.) by reviewing all
available clinical records, including death certiﬁcates, to ascertain the
underlying cause of death. Consequently, all SPNs and causes of death were
validated.
BCCSS Questionnaire
Between 2001 and 2007, all survivors who were alive and age . 16
years were sent a 40-page questionnaire by their primary care physician on
behalf of the BCCSS.18 In total, 947 of all eligible survivors of WT (70.5%)
completed and returned the questionnaire.17 The BCCSS questionnaire
inquired about potential adverse health and social outcomes of childhood
cancer and its treatment, including questions regarding health status
(Short Form 36 [SF-36]), health services use, medical conditions, medical
procedures, marriage, adverse pregnancy outcomes (eg, miscarriage,
stillbirth, preterm birth), smoking and alcohol consumption, and edu-
cational achievements.
Ethical approval for the BCCSS was obtained from the relevant
multicenter research ethics committee and every local research ethics
committee in Great Britain (212 total).
Statistical Analysis
Cause-speciﬁc mortality. Numbers of observed deaths among sur-
vivors of WT were compared with the number of expected deaths on the
basis of the population of England and Wales. The at-risk period began
5 years after the initial diagnosis of childhood WT and continued until
the ﬁrst occurrence of emigration, death, or exit (December 31, 2010).
Standardized mortality ratios (SMR) for speciﬁc causes of death were
calculated as the ratio of observed deaths versus the expected number of
deaths. Absolute excess risks (AERs) were calculated from observed deaths
minus the expected number of deaths and divided by the number of
person-years at risk multiplied by 10,000. The cumulative mortality for
speciﬁc causes of death was estimated by treating other causes of death as
competing risks.19
SPNs. The at-risk period for developing an SPN began 5 years after
the diagnosis of WT and continued until the ﬁrst occurrence of SPN,
emigration, death, or exit (December 31, 2006). Multiple observed SPNs
per survivor were permitted for comparison with those expected from the
general population to avoid bias, but only the ﬁrst SPN was considered in
measures of cumulative risk. Standardized incidence ratios, AERs, and
cumulative risk of developing an SPN were calculated as described in
“Cause-speciﬁc mortality” in relation to death.
Health status: SF-36. Health status was measured by using the SF-36
questionnaire.20 To compare SF-36 scale scores observed among survivors
of WT with the general population, we used normative data from the
Oxford Healthy Life Survey (OHLS).21 For each SF-36 scale, the difference
in mean scores between survivors of WTand OHLSwas calculated by using
linear regression, which adjusted for age and sex. In addition, we examined
Table 1. Characteristics of All Survivors of WT in the BCCSS and of All Those
Who Completed a Questionnaire (N = 1,441)
Characteristic
All WT Survivors
(N = 1,441)
Completed
Questionnaire
Returned
(n = 947)
No Completed
Questionnaire
Returned
(n = 494)
Sex
Male 733 (51) 436 (46) 297 (60)
Female 708 (49) 511 (54) 197 (40)
Age at diagnosis, years
Mean 3.3 3.3 3.3
Median 2.8 2.9 2.7
0-4 1,156 (80.2) 760 (80.3) 396 (80.2)
5-9 252 (17.5) 166 (17.5) 86 (17.4)
10-14 33 (2.3) 21 (2.2) 12 (2.4)
Age at questionnaire
completion, years*
Mean N/A 28.3 N/A
5-9 N/A 0 (0.0) N/A
10-19 N/A 221 (23.3) N/A
20-29 N/A 350 (37.0) N/A
30-39 N/A 261 (27.6) N/A
40-49 N/A 90 (9.5) N/A
50-59 N/A 22 (2.3) N/A
$ 60 N/A 3 (0.3) N/A
Years from WT
diagnosis†
5-9 30 (2.1) 0 (0.0) 30 (6.1)
10-19 94 (6.5) 27 (2.9) 67 (13.6)
20-29 349 (24.2) 234 (24.7) 115 (23.3)
30-39 652 (45.2) 455 (48.0) 197 (39.9)
$ 40 316 (21.9) 231 (24.4) 85 (17.2)
On long-term hospital
follow-up‡
Yes N/A 360 (38.3) N/A
No N/A 546 (58.0) N/A
Missing N/A 35 (3.7) N/A
Treated with abdominal
radiotherapy
Yes 756 (52.5) 489 (51.7) 267 (54.1)
No 164 (11.4) 111 (11.7) 53 (10.7)
Missing 521 (36.1) 347 (36.6) 174 (35.2)
Treated with
chemotherapy
Yes 701 (48.6) 460 (48.6) 241 (48.8)
No 203 (14.1) 125 (13.2) 78 (15.8)
Missing 537 (37.3) 362 (38.2) 175 (35.4)
Surgery
Yes 921 (63.9) 598 (63.2) 323 (65.4)
No 13 (0.9) 9 (0.9) 4 (0.8)
Missing 507 (35.2) 340 (35.9) 167 (33.8)
NOTE. All data are given as No. (%) unless otherwise noted.
Abbreviations: BCCSS, British Childhood Cancer Survivor Study; N/A, not
applicable; WT, Wilms tumor.
*The BCCSS questionnaire was sent out to survivors age $ 16 years.
†Years of follow-up after initial diagnosis. Percentages correspond to the total
number in cohort or the number of those who completed questionnaire.
‡Regular hospital follow-up appointments in relation to the childhood cancer or
its treatment.
www.jco.org © 2016 by American Society of Clinical Oncology 1773
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responses to the individual questions (items) underlying the speciﬁc SF-36
scales by comparing the directly standardized percentage (for age and sex)
of survivors of WTwho reported a limitation or other problem with that
reported by the general population.
Adverse pregnancy outcomes. To investigate the risks of adverse
pregnancy outcomes, logistic regression models were used to calculate
odds ratios (ORs) to compare the likelihood of low birth weight, preterm
births, and miscarriage between pregnancy outcomes among female
survivors of WT who were treated with abdominal radiotherapy with
female survivors of non-WT childhood cancers who did not receive
abdominal radiotherapy. Most female survivors of WT (87%) who
reported being pregnant at least once had been treated with abdominal
irradiation.
Smoking status, alcohol consumption, and education level. Among
those survivors of WTwho completed the BCCSS questionnaire, smoking,
alcohol consumption, and educational attainment were compared with the
general population by using data from the nationwide General Household
Survey (GHS).22 Adjustment for confounders and classiﬁcation of current
regular smokers, alcohol consumption, and educational attainment have
been deﬁned in previous BCCSS studies.23-25 For each outcome, ORs that
compared survivors of WT with the GHS were calculated by using
multivariable logistic regression with a generalized estimating equation
modiﬁcation that took into account clustering within the GHS; these ORs
were adjusted for attained age and sex.
Marital status. To investigate marital status among survivors of WT,
ORs of ever being married, stratiﬁed by sex and attained age, were cal-
culated by using data from the National Marriage Registry as the reference
population.26 Age-speciﬁc ORs were then pooled into one overall OR by
using the Mantel-Haenszel method for combining ORs.27
Health services use. The frequency of doctor consultations, hospital
outpatient visits, day patient hospitalizations, and inpatient hospital-
izations were evaluated by calculating ORs to compare survivors of WT
with the GHS by using a multivariable logistic regression model. ORs were
adjusted for attained age, sex, educational attainment and were stratiﬁed by
whether survivors were on regular long-term hospital follow-up stemming
from their childhood cancer and its treatment.28
Statistical signiﬁcance for all analyses was deﬁned as a two-sided
P , .05. All analyses were carried out with STATA software (version 12;
STATA, College Station, TX; Computing Resource Center, Santa Monica,
CA).
RESULTS
Cohort Characteristics
Of the 1,441 survivors of WT in the cohort, 10% (n = 146)
had died, 2% (n = 31) emigrated, and 88% (n = 1,264) were alive
at the exit date (December 31, 2010). Characteristics of survivors
of WT who completed the questionnaire were similar to all
survivors of WT in the BCCSS cohort (Table 1). Regarding
mortality, there were 38,803 person-years from 5-year survival,
with mean and median follow-up of 26.9 years and 26.0 years,
respectively. Table 1 indicates that 756 (82%) of 920 survivors
were exposed to direct abdominal radiotherapy, and only 164
were known to be unexposed. Consequently, the analysis of the
entire cohort, used for analysis of deaths and SPNs, corresponds
to a group overwhelmingly exposed to direct abdominal
radiotherapy.
Cause-Specific Mortality
Survivors experienced greater than ﬁve times the number of
deaths expected (SMR, 5.4; 95% CI, 4.6 to 6.4 deaths), with 30.7
additional deaths (95%CI, 24.6 to 36.8) per 10,000 person-years in
excess of that expected (Table 2). For speciﬁc causes of death,
with $ 20 observed deaths, results are reported separately. In
multiplicative terms, cause-speciﬁc mortality was greatest for SPNs
(SMR, 7.3; 95% CI, 5.3 to 9.8) and for cardiac disease (SMR, 10.1;
95% CI, 6.5 to 14.9). Regarding AER, the greatest excess risk
resulted from SPNs, which accounted for 32% of all excess deaths.
This was followed by deaths as a result of recurrence and cardiac
causes, which accounted for 21% and 19% of the excess deaths,
respectively. Deaths from recurrence mostly occurred relatively
early, with 22 of 25 such deaths between 5 and 14 years, three of
25 between 15 and 24 years, and none from 25 years after diagnosis
(not shown in tables). The AER as a result of all causes of death
except recurrence was 14 excess deaths (per 10,000 person-years)
between 5 and 29 years after WT diagnosis; however, this increased
eight-fold to 108.4 excess deaths beyond 30 years, which is
equivalent to one additional death per 100 survivors each year
(Table 3). From 30 years afterWT diagnosis, deaths from SPNs and
cardiac disease accounted for 50% and 25% of the total number of
excess deaths, respectively.
Cumulative mortality from recurrence was 1.8% by 30 years
after WT diagnosis, and it remained the same by 50 years as there
were no more deaths as a result of recurrence. Cumulative
mortality from all causes except recurrence was 5.4% by 30 years
after WT diagnosis, but this increased substantially to 22.7% by
50 years. By 50 years from WT diagnosis, the cumulative mortality
from SPNs and cardiac diseases were 8.2% and 6.3%, respectively
(Fig 1).
There were 25 cardiac deaths according to the underlying
cause of death on the death certiﬁcate, and we summarize the
results of a comprehensive review of these causes of death, taking
account of all hospital records and autopsy reports still available
(Appendix Table A1, online only). This comprehensive review
ascertained that four deaths were because of renal failure; nine
from myocardial infarction (four with chest irradiation and/or
lung metastases); seven from cardiomyopathy and/or heart failure
(six with chest irradiation); three from pulmonary embolism; and
two from other causes.
SPNs
The cumulative risk of developing an SPN was 3.7% (95% CI,
2.7% to 5.0%) by 30 years after WT diagnosis, which increased to
16.4% (95% CI, 10.7% to 23.2%) by 50 years (Fig 2). The most
common SPNs were those of digestive sites, which occurred in
17 survivors ofWT; sevenwere bowel cancers, and the other affected
sites are speciﬁed in Table 4—all 17 survivors had previously
received abdominal radiotherapy. Of SPNs . 40% developed
beyond 30 years after diagnosis of WT, and 10 of 17 digestive SPNs
developed in this period, which accounted for 41% of the excess
number of cancers in this follow-up period. All survivors ofWTwho
developed breast cancer had previously received either abdominal or
chest radiotherapy.
Health Status: SF-36
Survivors of WT scored signiﬁcantly lower than did the
general population on two of the eight SF-36 scales: physical
functioning (difference in means [D], 21.8; 95% CI, 23.3
1774 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
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to 20.9) and general health perception (D, 26.7; 95% CI, 28.1
to 25.2; Appendix Table A2, online only). However, survivors
of WT reported signiﬁcantly better role–emotional functioning
(D, 3.4; 95% CI, 1.2 to 5.6) than did the general population. When
examining the responses to individual questions which comprise
the physical functioning scale, survivors of WT reported sig-
niﬁcantly greater limitations on most items compared with the
general population (Appendix Fig A1, online only). When
examining responses to the individual questions which comprise
the general health perception scale, survivors of WT reported
greater agreement that their health was worse in relation to each
question compared with the general population (Appendix Fig A2,
online only).
Pregnancy Outcomes
Of the 511 female survivors of WTwho completed the BCCSS
questionnaire, 412 pregnancies were reported by 184 women, of
which 32% resulted in low birth weight, 35% in a preterm delivery,
and 22% in a miscarriage for those who responded to the relevant
questions and had received abdominal irradiation. Female survi-
vors of WTwho were treated with abdominal radiotherapy were at
an increased risk of giving birth to a low-birth-weight baby (OR,
3.3; 95% CI, 2.2 to 4.9) and of giving birth preterm (OR, 3.1; 95%
CI, 2.1 to 4.7) compared with survivors of non-WT childhood
cancer who were not treated with abdominal radiotherapy.
Pregnancy analyses were stratiﬁed by eras of treatment (, 1970
and $ 1970); however, no statistical differences were found
(P $ .386; Appendix Table A3, online only).
Smoking, Alcohol, Education, and Marriage
Compared with the general population, survivors of WT
were less likely to be regular smokers (OR, 0.7; 95% CI, 0.6 to
0.8), to consume alcohol (OR, 0.7; 95% CI, 0.6 to 0.9), or to
consume harmful amounts of alcohol (OR, 0.5; 95% CI, 0.3
to 0.7). Survivors of WT did not signiﬁcantly differ from the
general population in achieving speciﬁc levels of education (all
P values. .05). Male survivors were signiﬁcantly less likely to be
married (OR, 0.7; 95% CI, 0.5 to 0.9) compared with the general
population.
Health Services Use
Compared with the general population, survivors of WTwere
signiﬁcantly more likely to attend hospital outpatients (OR, 2.6;
95% CI, 2.2 to 3.1) at least once in the last 3 months, be hospi-
talized as a day patient (OR, 1.7; 95% CI, 1.3 to 2.1) at least once in
the last year, and be hospitalized as an inpatient (OR, 2.0; 95% CI,
1.6 to 2.6) at least once in the last year. When stratiﬁed by whether
survivors of WT were on long-term hospital follow-up for their
childhood cancer or its treatment, survivors not on long-term
hospital follow-up (n = 546) were still signiﬁcantly more likely to
be hospitalized as an outpatient (OR, 2.1; 95% CI, 1.7 to 2.6), day
patient (OR, 1.5; 95% CI, 1.1 to 2.0), and inpatient (OR, 1.9; 95%
CI, 1.4 to 2.6) compared with the general population. Survivors of
WTwhowere on such long-term hospital follow-up (n = 360) were
even more likely to be hospitalized as an outpatient (OR, 3.5; 95%
CI, 2.7 to 4.6), day patient (OR, 1.9; 95% CI, 1.3 to 2.7), and
inpatient (OR, 2.3; 95% CI, 1.6 to 3.5).
Table 2. Cause-Speciﬁc SMRs and AERs for Survivors of WT (N = 1,441)
Cause of Death Obs/Exp SMR (95% CI) AER (95% CI)* % of Total AER
All causes overall 146/26.8 5.4 (4.6 to 6.4) 30.7 (24.6 to 36.8) 100
Years from diagnosis
5-9 25/1.6 15.7 (10.2 to 23.2) 36.2 (21.0 to 51.3)
10-19 29/6.1 4.8 (3.2 to 6.9) 16.5 (8.9 to 24.0)
20-29 37/6.8 5.5 (3.8 to 7.5) 21.1 (11.1 to 31.1)
30-39 27/5.9 4.6 (3.0 to 6.6) 38.2 (19.8 to 56.7)
$ 40 28/6.5 4.3 (2.9 to 6.3) 92.7 (48.1 to 137.4)
Infection 5/0.6 8.7 (2.8 to 20.2) 1.1 (0.0 to 2.3) 4
Recurrence 25/0 — 6.4 (3.9 to 9.0) 21
SPN 44/6.0 7.3 (5.3 to 9.8) 9.8 (6.4 to 13.1) 32
Blood 0/0.1 N/A 0.0 (N/A) 0
Endocrine 0/0.6 N/A 20.1 (20.1 to 20.1) 0
Mental 1/0.9 1.1 (0.0 to 6.2) 0.0 (20.5 to 0.5) 0
Nervous 3/1.3 2.2 (0.5 to 6.6) 0.4 (20.4 to 1.3) 1
Cardiac 25/2.5 10.1 (6.5 to 14.9) 5.8 (3.3 to 8.3) 19
Respiratory 6/1.2 4.9 (1.8 to 10.7) 1.2 (0.0 to 2.5) 4
Digestive 6/1.5 3.9 (1.4 to 8.5) 1.2 (20.1 to 2.4) 4
Muscoskeletal 0/0.2 N/A 0.0 (N/A) 0
Genitourinary 6/0.2 33.1 (12.2 to 72.1) 1.5 (0.3 to 2.7) 5
Perinatal 2/0.7 3.0 (0.4 to 10.8) 0.3 (20.4 to 1.1) 1
External 19/9.6 2.0 (1.2 to 3.1) 2.1 (0.2 to 4.6) 7
Other 4/1.4 2.9 (0.8 to 7.3) 0.7 (20.3 to 1.8) 2
NOTE. Calculation of SMR for deaths from recurrence ofWTwould not be appropriate because the expectedmortality rate in the general population would be zero. AER
for recurrence was calculated as the incidence rate per 10,000 person-years. CIs for SMR were calculated by using the approximate method if number of deaths$ 100
and the Poisson exact method if number of deaths , 100.29 Perinatal deaths refer to causes resulting from congenital abnormalities (two). External causes of death
comprise accidents (seven motor accidents and ﬁve accidental poisonings), suicides (two) and other (one death could not be determined as accident or suicide and one
death was from a medical procedure). Other causes of death were either unknown or ill-deﬁned (two) or from general symptoms (one) and stroke (one).
Abbreviations: AER absolute excess risk; Exp, expected; N/A, not applicable; Obs, observed; SMR, standardized mortality ratio; SPN, second primary neoplasm; WT,
Wilms tumor.
*Overall AER for all causes of death was 30.7 per 10,000 person-years but because of rounding, the speciﬁc causes of death sum to 30.4.
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DISCUSSION
New ﬁndings include the identiﬁcation of a substantial increase
in cumulative mortality as a result of causes of death other
than recurrence in the period from 30 to 50 years after WT
diagnosis—increasing from 5.4% to 22.7%, which corresponds to
one extra death per 100 survivors per year. Consistent with our
study, a previous US-based, large-scale study3 found that cumu-
lative mortality at 30 years from WT diagnosis was approximately
3%, but thus far, to our knowledge, no study has demonstrated the
substantial increase in mortality from 30 to 50 years from WT
diagnosis. The excess of deaths after 30 years was mainly attrib-
utable to SPNs (50%) and cardiac-related deaths (25%), which
together accounted for 75% of all excess deaths. The AER for the
ﬁrst 30 years after diagnosis is consistent with that found in the
National Wilms Tumor Study30, but this study also did not have
sufﬁcient follow-up to demonstrate a substantial increase in the
AER beyond 30 years from diagnosis as observed in the current
study.
The excess of SPNs during the initial 30 years from WT
diagnosis was comparable to that reported in previous studies.6,31
Beyond 30 years from WT diagnosis, previous studies had in-
sufﬁcient follow-up to satisfactorily assess evidence for an excess.
Our cumulative risk increased from 3.7% at 30 years to 16.4% at
50 years. Beyond 30 years from WT diagnosis, there were 4.5 excess
cancers observed per 1,000 survivors per year. This excess was
mainly attributable to digestive cancers (41%) and breast cancers
(7%), together accounting for 48% of the total excess of cancers.
All survivors of WT who developed a digestive SPN had received
abdominal radiotherapy, and all survivors who developed breast
cancer received either abdominal or chest radiotherapy. We have
previously reported the strong link between abdominopelvic
irradiation and subsequent bowel cancer.32 Speciﬁcally, the risk of
developing bowel cancer among survivors of childhood cancer
who were treated with direct abdominopelvic irradiation is at least
Table 3. AER of Speciﬁc Causes of Death by Years of Follow-Up as a Proportion of Total AER
Cause of Death
AER , 30 Years From Diagnosis AER $ 30 Years From Diagnosis
Obs/Exp AER (95% CI) % of Total AER Obs/Exp AER (95% CI) % of Total AER
Recurrence 25/0 7.2 (4.4 to 10.0) 34 0/0 0.0 (N/A) 0
SPN 18/2.8 4.4 (2.0 to 6.8) 21 26/3.2 53.8 (30.2 to 77.4) 50
Cardiac 12/0.9 3.2 (1.2 to 5.2) 15 13/1.5 27.0 (10.3 to 43.7) 25
External 14/8.3 1.6 (20.5 to 3.7) 7 5/1.2 8.9 (21.4 to 19.2) 8
All other causes 22/5.5 5.0 (2.3 to 7.7) 23 11/2.9 19.1 (3.8 to 34.4) 17
All deaths* 91/17.8 21.2 (15.8 to 26.6) 100 55/9.0 108.4 (74.1 to 142.7) 100
NOTE. AER presented per 10,000 person-years.
Abbreviations: AER, absolute excess risk; Exp, expected; N/A, not applicable; Obs, observed; SPN, second primary neoplasm.
*AER for all causes of death was 21.2 per 10,000 person-years, 30 years from diagnosis and 108.4 per 10,000 person-years$ 30 years from diagnosis, but because of
rounding, the speciﬁc causes of death sum to 21.4 and 108.8, respectively.
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the same as that observed among individuals who have at least
two ﬁrst-degree relatives diagnosed with bowel cancer, and for
whom colonoscopy is currently recommended, from age 35 to
45 years33 or from age 50 years.34 This raises the serious question
of whether irradiated survivors of WT, who comprise the majority
of survivors of childhood cancer who were treated with direct
abdominopelvic irradiation, should be similarly recommended
for colonoscopy.
Previous studies have shown that survivors of WT reported
adverse health status outcomes comparable to our study,3,35 that is,
lower general health perception and physical function. In addition,
survivors of WT also reported lower overall health status in pre-
vious studies.15,36-38 Survivors of WT in our study reported that
role–emotional was signiﬁcantly higher than OHLS; however, this
is likely a result of ceiling effects because role–emotional was
measured by three categories, which caused a clustering of scores at
the maximum level.39
Consistent with previous studies,7-9,14,40 completed preg-
nancies were more likely to be premature and to result in low birth
weight. The results of the current and previous studies suggest that
female survivors who were treated with abdominal radiation
should be carefully monitored during pregnancy.
With respect to social outcomes, and consistent with previous
studies, survivors of WT seem to have a healthier life style, being
less likely to be regular smokers41,42 and consuming lower amounts
of alcohol than the general population. Similar to a previous study,
male survivors were less likely to be married than the general
population.43
Survivors ofWTwere more likely to visit the hospital and to be
hospitalized, regardless of whether they were on regular long-term
hospital follow-up as a result of their childhood cancer or its
treatment, a ﬁnding that is similar to previous studies.3,44
A limitation of our study was the lack of detailed information
on radiotherapy and chemotherapy treatment administered to
survivors of WT. It is also important to acknowledge that survivors
included in the cohort were treated between 1940 and 1991;
therefore, our ﬁndings are unlikely to be generalizable to survivors
treated in more recent years because of changes in exposure to
different treatments. For example, the vast majority (82%) of
survivors presented here had received radiotherapy as part of their
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Fig 2. Observed and expected cumulative
incidence of developing a second primary
neoplasm among 1,441 survivors of Wilms
tumor, with 95% CIs.
Table 4. SIRs and AERs for Developing Speciﬁc SPNs After Diagnosis With WT
Outcome Obs/Exp SIR (95% CI) AER (95% CI)
AER (95% CI; No.)
, 30 Years From Diagnosis
AER (95% CI; No.) $ 30
Years From Diagnosis
All 71/15.1 4.7 (3.7 to 5.9) 16.6 (11.7 to 21.5) 11.8 (7.4 to 16.1; 41) 44.6 (23.0 to 66.3; 30)
Digestive* 17/1.3 13.0 (7.6 to 20.9) 4.7 (2.3 to 7.1) 2.3 (0.5 to 4.1; 7) 18.2 (5.7 to 30.7; 10)
Genitourinary 9/3.5 2.6 (1.2 to 4.9) 1.6 (20.1 to 3.4) 1.8 (0.0 to 3.6; 7) 0.5 (25.1 to 6.1; 2)
Breast 9/2.9 3.1 (1.4 to 5.8) 1.8 (0.1 to 3.5) 1.5 (20.4 to 1.8; 5) 3.3 (24.6 to 11.2; 4)
Bone 6/0.3 20.6 (7.5 to 44.8) 1.7 (0.3 to 3.1) 1.6 (0.1 to 3.2; 5) 2.0 (22.0 to 5.9; 1)
NOTE. AER is shown per 10,000 person-years. Thirty other SPNs include soft tissue sarcoma (six), unknown primary site (ﬁve), glioma (three), leukemia (three ), non-
Hodgkin lymphoma (three), thyroid (three), melanoma (two), adrenal (one), Hodgkin’s lymphoma (one), mesothelioma (one), leiomyosarcoma (one), and oral (one).
Abbreviations: AER, absolute excess risk; Exp, expected; Obs, observed; SIR, standardized incidence ratio; SPN, second primary neoplasm; WT, Wilms tumor.
*The 17 digestive SPNs comprise bowel (seven), retroperitoneum/peritoneum (four), liver (two), pancreas (one), small intestine (one), pyloric antrum (one), and unknown
digestive site (one).
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initial treatment. In contrast, only 27% of nonanaplastic patients
with WTwho were included within a relatively recent randomized
clinical trial (UKW3),45 which recruited between 1991 and 2001,
received radiotherapy as part of their initial treatment. Never-
theless, there are still an entire cohort of survivors being seen in
follow-up clinics or discharged into the community who were
treated before 1991 and our evidence relates directly to them.
In conclusion, between 30 and 50 years from diagnosis,
survivors of WT are at a substantially increased risk of premature
mortality, and 75% of excess deaths were accounted for by SPNs
and cardiac diseases. Radiotherapy exposure was a risk factor for
both outcomes. The proportion of patients with WT who were
exposed to radiotherapy has reduced substantially in recent dec-
ades because of initiatives such as the SIOP WT 2001 clinical trial,
which sought to reduce late effects.45 However, the majority of
current survivors, $ 30 years from diagnosis, received radio-
therapy. Surveillance of this group should focus on SPNs, in
particular, bowel and breast cancers, and cardiac conditions as
these account for 50% and 25% of total excess deaths observed,
respectively.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS
OF INTEREST
Disclosures provided by the authors are available with this article at
www.jco.org.
AUTHOR CONTRIBUTIONS
Conception and design: Kwok F. Wong, Raoul C. Reulen, Kathryn
Pritchard-Jones, Helen C. Jenkinson, Elaine Sugden, Gill Levitt, Clare
Frobisher, Michael M. Hawkins
Administrative support: David L. Winter, Julie Kelly
Collection and assembly of data: Kwok F. Wong, Raoul C. Reulen, David
L.Winter, Julie Kelly, Emma R. Lancashire, Elaine Sugden, Gill Levitt, Clare
Frobisher, Michael M. Hawkins
Data analysis and interpretation: Kwok F. Wong, Raoul C. Reulen, David
L. Winter, Joyeeta Guha, Miranda M. Fidler, Clare Frobisher, Michael M.
Hawkins
Manuscript writing: All authors
Final approval of manuscript: All authors
REFERENCES
1. Stiller CA, Kroll ME, Pritchard-Jones K: Pop-
ulation survival from childhood cancer in Britain
during 1978-2005 by eras of entry to clinical trials.
Ann Oncol 23:2464-2469, 2012
2. Reulen RC, Winter DL, Frobisher C, et al:
Long-term cause-speciﬁc mortality among survivors
of childhood cancer. JAMA 304:172-179, 2010
3. Termuhlen AM, Tersak JM, Liu Q, et al:
Twenty-ﬁve year follow-up of childhood Wilms
tumor: A report from the Childhood Cancer Survivor
Study. Pediatr Blood Cancer 57:1210-1216, 2011
4. Reulen RC, Frobisher C, Winter DL, et al:
Long-term risks of subsequent primary neoplasms
among survivors of childhood cancer. JAMA 305:
2311-2319, 2011
5. BreslowNE, Takashima JR,Whitton JA, et al:
Second malignant neoplasms following treatment
for Wilm’s tumor: A report from the National Wilms’
Tumor Study Group. J Clin Oncol 13:1851-1859,
1995
6. Breslow NE, Lange JM, Friedman DL, et al:
Secondary malignant neoplasms after Wilms tumor:
An international collaborative study. Int J Cancer 127:
657-666, 2010
7. Reulen RC, Zeegers MP, Wallace WH, et al:
Pregnancy outcomes among adult survivors of
childhood cancer in the British Childhood Cancer
Survivor Study. Cancer Epidemiol Biomarkers Prev
18:2239-2247, 2009
8. Green DM, Lange JM, Peabody EM, et al:
Pregnancy outcome after treatment forWilms tumor:
A report from the national Wilms tumor long-term
follow-up study. J Clin Oncol 28:2824-2830, 2010
9. Green DM, Whitton JA, Stovall M, et al:
Pregnancy outcome of female survivors of childhood
cancer: A report from the Childhood Cancer Survivor
Study. Am J Obstet Gynecol 187:1070-1080, 2002
10. Wright KD, Green DM, Daw NC: Late effects
of treatment forWilms tumor. Pediatr Hematol Oncol
26:407-413, 2009
11. Green DM, Nolan VG, Kawashima T, et al:
Decreased fertility among female childhood cancer
survivors who received 22-27 Gy hypothalamic/
pituitary irradiation: A report from the Childhood
Cancer Survivor Study. Fertil Steril 95:1922-1927,
2011
12. Green DM, Kawashima T, Stovall M, et al:
Fertility of female survivors of childhood cancer: A
report from the childhood cancer survivor study.
J Clin Oncol 27:2677-2685, 2009
13. Green DM, Sklar CA, Boice JD Jr, et al:
Ovarian failure and reproductive outcomes after
childhood cancer treatment: Results from the
Childhood Cancer Survivor Study. J Clin Oncol 27:
2374-2381, 2009
14. Signorello LB, Cohen SS, Bosetti C, et al:
Female survivors of childhood cancer: Peterm birth
and low birth weight among their children. J Natl
Cancer Inst 98:1453-1461, 2006
15. Nathan PC, Ness KK, Greenberg ML, et al:
Health-related quality of life in adult survivors of
childhood Wilms tumor or neuroblastoma: A report
from the Childhood Cancer Survivor Study. Pediatr
Blood Cancer 49:704-715, 2007
16. Carli M, Frascella E, Tournade MF, et al:
Second malignant neoplasms in patients treated on
SIOP Wilms tumour studies and trials 1, 2, 5, and 6.
Med Pediatr Oncol 29:239-244, 1997
17. HawkinsMM, Lancashire ER,Winter DL, et al:
The British Childhood Cancer Survivor Study:
Objectives, methods, population structure, response
rates and initial descriptive information. Pediatr Blood
Cancer 50:1018-1025, 2008
18. University of Birmingham. The British Child-
hood Cancer Survivor Study questionnaire. http://
www.birmingham.ac.uk/Documents/college-mds/
haps/projects/cancerPH/bccss/completeqf.pdf
19. Coviello V, Boggess M: Cumulative incidence
estimation in the presence of competing risks. Stata
J 4:103-112, 2004
20. Reulen RC, Winter DL, Lancashire ER, et al:
Health-status of adult survivors of childhood cancer:
A large-scale population-based study from the British
Childhood Cancer Survivor Study. Int J Cancer 121:
633-640, 2007
21. Jenkinson C, Coulter A, Wright L: Short form
36 (SF36) health survey questionnaire: Normative
data for adults of working age. BMJ 306:1437-1440,
1993
22. Rickards L, Fox K, Roberts C, Fletcher L,
Goddard E (eds): Living in Britain. No. 31. Results
from the 2002 General Household Survey. London,
United Kingdom, Ofﬁce for National Statistics, 2004
23. Frobisher C, Winter DL, Lancashire ER, et al:
Extent of smoking and age at initiation of smoking
among adult survivors of childhood cancer in Britain.
J Natl Cancer Inst 100:1068-1081, 2008
24. Frobisher C, Lancashire ER, Reulen RC, et al:
Extent of alcohol consumption among adult survivors
of childhood cancer: The British Childhood Cancer
Survivor Study. Cancer Epidemiol Biomarkers Prev
19:1174-1184, 2010
25. Lancashire ER, Frobisher C, Reulen RC, et al:
Educational attainment among adult survivors of
childhood cancer in Great Britain: A population-
based cohort study. J Natl Cancer Inst 102:
254-270, 2010
26. Frobisher C, Lancashire ER, Winter DL, et al:
Long-term population-based marriage rates among
adult survivors of childhood cancer in Britain. Int J
Cancer 121:846-855, 2007
27. Hailpern SM, Visintainer PF: Odds ratios and
logistic regression: Further examples of their use and
interpretation. Stata J 3:213-225, 2003
28. Rebholz CE, Reulen RC, Toogood AA, et al:
Health care use of long-term survivors of childhood
cancer: The British Childhood Cancer Survivor Study.
J Clin Oncol 29:4181-4188, 2011
29. BreslowNE, Day NE (eds): Statistical Methods
in Cancer Research, Volume 2. Lyon, France, WHO
IARC Scientiﬁc Publications, 1987
30. Cotton CA, Peterson S, Norkool PA, et al: Early
and late mortality after diagnosis of Wilms tumor.
J Clin Oncol 27:1304-1309, 2009 [Erratum: J Clin
Oncol 27:4819, 2009]
31. Friedman DL, Whitton J, Leisenring W, et al:
Subsequent neoplasms in 5-year survivors of child-
hood cancer: The Childhood Cancer Survivor Study.
J Natl Cancer Inst 102:1083-1095, 2010
32. Taylor AJ, Winter DL, Pritchard-Jones K, et al:
Second primary neoplasms in survivors of Wilms’
tumour—A population-based cohort study from the
1778 © 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Wong et al
Downloaded from ascopubs.org by UNIVERSITY BIRMINGHAM on March 2, 2017 from 147.188.108.081
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
British Childhood Cancer Survivor Study. Int J Cancer
122:2085-2093, 2008
33. Cancer Research UK: Screening for people at
high risk of bowel cancer. http://www.cancerresearchuk.
org/about-cancer/type/bowel-cancer/about/screening/
who-is-screened-for-bowel-cancer
34. Cairns SR, Scholeﬁeld JH, Steele RJ, et al:
Guidelines for colorectal cancer screening and sur-
veillance in moderate and high risk groups (update
from 2002). Gut 59:666-689, 2010
35. Speechley KN, Barrera M, Shaw AK, et al:
Health-related quality of life among child and ado-
lescent survivors of childhood cancer. J Clin Oncol
24:2536-2543, 2006
36. Mo¨rt S, Salantera¨ S, Matoma¨ki J, et al: Self-
reported health-related quality of life of children and
adolescent survivors of extracranial childhood
malignancies: A Finnish nationwide survey. Qual Life
Res 20:787-797, 2011
37. Hudson MM, Mertens AC, Yasui Y, et al:
Health status of adult long-term survivors of child-
hood cancer: A report from the Childhood Cancer
Survivor Study. JAMA 290:1583-1592, 2003
38. Zeltzer LK, Recklitis C, Buchbinder D, et al:
Psychological status in childhood cancer survivors: A
report from the Childhood Cancer Survivor Study.
J Clin Oncol 27:2396-2404, 2009
39. Reulen RC, Zeegers MP, Jenkinson C, et al:
The use of the SF-36 questionnaire in adult survivors
of childhood cancer: Evaluation of data quality, score
reliability, and scaling assumptions. Health Qual Life
Outcomes 4:77, 2006
40. Madanat-Harjuoja LM, Malila N, La¨hteenma¨ki
PM, et al: Preterm delivery among female survivors
of childhood, adolescent and young adulthood can-
cer. Int J Cancer 127:1669-1679, 2010
41. Carswell K, Chen Y, Nair RC, et al: Smoking
and binge drinking among Canadian survivors of
childhood and adolescent cancers: A comparative,
population-based study. Pediatr Blood Cancer 51:
280-287, 2008
42. Haupt R, Byrne J, Connelly RR, et al: Smoking
habits in survivors of childhood and adolescent
cancer. Med Pediatr Oncol 20:301-306, 1992
43. Pastore G, Magnani C, Mosso ML, et al:
Marriage and offspring in adult long-term survivors of
childhood cancer: A study from the Childhood Cancer
Registry of the Piedmont region, Italy. Ital J Pediatr
28:121-127, 2002
44. Oefﬁnger KC, Mertens AC, Hudson MM, et al:
Health care of young adult survivors of childhood
cancer: A report from the Childhood Cancer Survivor
Study. Ann Fam Med 2:61-70, 2004
45. Pritchard-Jones K, Moroz V, Vujanic G, et al:
Treatment and outcome of Wilms’ tumour patients:
An analysis of all cases registered in the UKW3 trial.
Ann Oncol 23:2457-2463, 2012
n n n
www.jco.org © 2016 by American Society of Clinical Oncology 1779
Adverse Outcomes in Survivors of Childhood Wilms Tumor
Downloaded from ascopubs.org by UNIVERSITY BIRMINGHAM on March 2, 2017 from 147.188.108.081
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Risk of Adverse Health and Social Outcomes Up to 50 Years After Wilms Tumor: The British Childhood Cancer Survivor Study
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are
self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more
information about ASCO’s conﬂict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc.
Kwok F. Wong
No relationship to disclose
Raoul C. Reulen
No relationship to disclose
David L. Winter
No relationship to disclose
Joyeeta Guha
No relationship to disclose
Miranda M. Fidler
No relationship to disclose
Julie Kelly
No relationship to disclose
Emma R. Lancashire
No relationship to disclose
Kathryn Pritchard-Jones
No relationship to disclose
Helen C. Jenkinson
No relationship to disclose
Elaine Sugden
No relationship to disclose
Gill Levitt
No relationship to disclose
Clare Frobisher
No relationship to disclose
Michael M. Hawkins
No relationship to disclose
© 2016 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Wong et al
Downloaded from ascopubs.org by UNIVERSITY BIRMINGHAM on March 2, 2017 from 147.188.108.081
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
Acknowledgment
The British Childhood Cancer Survivor Study (BCCSS) beneﬁts from the contributions of the Ofﬁcers, Centers, and individual members
of the Children’s Cancer and Leukemia Group and the Regional Pediatric Cancer Registries. The BCCSS acknowledges the collaboration of
the Ofﬁce for National Statistics, the General Register Ofﬁce for Scotland, the National Health Service Information Centre, the regional
cancer registries, health authorities, and area health boards for providing general practitioner names and addresses as well as the general
practitioners nationwide who facilitated direct contact with survivors. In particular, we thank all survivors who completed a 40-page
questionnaire and all general practitioners who returned consent forms. Finally, we thank all BCCSS staff, who have given many years of
dedicated work to bring the BCCSS to fruition.
Appendix
The British Childhood Cancer Survivor Study (BCCSS) is a national collaborative undertaking guided by a steering group
comprised of Douglas Easton (chair), Michael Hawkins, Helen Jenkinson, Meriel Jenney, Raoul Reulen, Kathryn Pritchard-Jones,
Michael Stevens, Elaine Sugden, Andrew Toogood, and Hamish Wallace.
Vi
go
ro
us
 ac
tiv
iti
es
M
od
er
at
e a
cti
vit
ies
Lif
tin
g/
ca
rry
in
g 
gr
oc
er
ies
Cl
im
bi
ng
 se
ve
ra
l f
lig
ht
s o
f s
ta
irs
Cl
im
bi
ng
 o
ne
 fl
ig
ht
 o
f s
ta
irs
Be
nd
in
g/
kn
ee
lin
g/
sto
op
in
g
W
alk
in
g 
m
or
e t
ha
n 
on
e m
ile
W
alk
in
g 
ha
lf 
a m
ile
W
alk
in
g 
10
0 y
ar
ds
Ba
th
in
g/
dr
es
sin
g 
th
em
se
lve
s
0
10
20
30
40
50
60
70
Pe
rc
en
t L
im
ite
d 
(%
) 
General population
Wilms tumor survivors
Fig A1. Speciﬁc questions underlying the Short Form 36 Physical Function scale; directly standardized proportions with limitation in speciﬁc activities.
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Table A1. Results of a Comprehensive Review by Using Hospital Records and Autopsy Reports of 25 Causes of Death Relating to the 25 Deaths Coded as Cardiac on
the Death Certiﬁcate
Type of Circulatory Death Frequency Comments
Myocardial infarction 9 Four had chest radiotherapy and/or lung metastasis
documented
Cardiomyopathy/heart failure 7 Six had chest radiotherapy documented, two also had renal
failure; myocardial, lung, and liver ﬁbrosis at autopsy in two
Pulmonary embolism 3
Other 2 Comprised of one atrial myxoma and one alcoholic
cardiomyopathy
NOTE. Of the 25 deaths, four were considered deaths from renal failure. The age of death was . 50 years in only four persons.
Table A2. Differences in Mean SF-36 Scores Between Survivors of Wilms
Tumor (n = 947) and OHLS Reference Population
SF-36 Scale D (95% CI)*
Reported health change 0.0 (–1.1 to 1.1)
Physical function 21.8 (– 3.3 to –0.9)
Role–physical 21.2 (–3.3 to 0.9)
Role–emotional 3.4 (1.2 to 5.6)
Social functioning 20.1 (–1.4 to 1.3)
Mental health 0.6 (–0.6 to 1.8)
Vitality 0.0 (–1.4 to 1.4)
Bodily pain 0.3 (–1.2 to 1.9)
General health perception 26.7 (–8.1 to –5.2)
Abbreviations: D, differences in mean; OHLS, Oxford Healthy Life Survey; SF-
36, Short Form 36.
*Calculated scores were adjusted for age and sex.
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Table A3. ORs of Pregnancy Outcomes, Smoking Status, Alcohol Consumption, Education Level, Marriage Status, and Medical Care of Survivors of Wilms Tumor (n = 947)
Variable Proportion of Affected Outcomes (%) OR (95% CI)
Pregnancy outcome*
Females survivor
Low birth weight 61/192 (31.8) 3.3 (2.2 to 4.9)
Premature 66/187 (35.3) 3.1 (2.1 to 4.7)
Miscarriage 67/303 (22.1) 1.4 (0.9 to 2.1)
Partners of males survivors
Low birth weight 8/134 (6.0) 0.6 (0.3 to 1.2)
Premature 12/136 (8.8) 0.6 (0.3 to 1.3)
Miscarriage 30/202 (14.9) 1.2 (0.7 to 1.9)
Smoking†
Current regular smoker 220/934 (23.6) 0.7 (0.6 to 0.8)
Alcohol‡
Alcohol consumption 766/942 (81.3) 0.7 (0.6 to 0.9)
Consumption over recommendation 210/766 (27.4) 0.8 (0.7 to 1.0)
Consuming harmful doses 34/766 (4.4) 0.5 (0.3 to 0.7)
Education achievement§
Degree 133/672 (19.8) 0.9 (0.7 to 1.1)
Teaching qualiﬁcation 204/672 (30.4) 0.9 (0.7 to 1.1)
A-level 385/774 (49.8) 0.9 (0.8 to 1.1)
O-level 690/924 (74.7) 1.0 (0.8 to 1.1)
Marital statusk
Male 123/426 (28.9) 0.7 (0.5 to 0.9)
Female 197/505 (39.0) 1.0 (0.8 to 1.3)
Hospitalization¶
Talked to a doctor in the last 2 weeks 152/900 (16.9) 1.2 (1.0 to 1.5)
Not on long-term follow-up 88/549 (16.0) 1.1 (0.9 to 1.4)
On long-term follow-up 57/329 (17.3) 1.3 (1.0 to 1.8)
Attended hospital outpatient 229/897 (25.5) 2.6 (2.2 to 3.1)
Not on long-term follow-up 123/546 (22.5) 2.1 (1.7 to 2.6)
On long-term follow-up 101/329 (30.7) 3.5 (2.7 to 4.6)
Hospitalized as a day patient 118/904 (13.1) 1.7 (1.3 to 2.1)
Not on long-term follow-up 71/552 (12.9) 1.5 (1.1 to 2.0)
On long-term follow-up 43/330 (13.0) 1.9 (1.3 to 2.7)
Hospitalized as an inpatient 93/904 (10.3) 2.0 (1.6 to 2.6)
Not on long-term follow-up 55/553 (10.0) 1.9 (1.4 to 2.6)
On long-term follow-up 36/329 (10.9) 2.3 (1.6 to 3.5)
NOTE. Total numbers represent the number of survivors of Wilms tumor that answered a question relating to the speciﬁc outcome on the British Childhood Cancer
Survivors Study questionnaire or, in the case of pregnancies, the total number of pregnancies in irradiated female survivors of Wilms tumor.
Abbreviation: OR, odds ratio.
*Modeled as pregnancies of female survivors of Wilms tumor who received abdominal radiotherapy versus pregnancies of female survivors of any other childhood
cancer who did not receive abdominal radiotherapy. There were 412 pregnancies from female survivors and 235 pregnancies from partners of male survivors. Models
were adjusted for maternal age and pregnancy order. Low birth weight was deﬁned as any birth weight , 2,500 g. Preterm birth was deﬁned as gestational age , 37
weeks.
†Adjusted for sex, attained age, marital status, socioeconomic classiﬁcation, and educational attainment.
‡Controlled for attained age, sex, legal marital status, socioeconomic classiﬁcations, educational attainment, and region, and took into account the General Household
Survey weighting factor for the likelihood of consuming over the recommendations for weekly alcohol units or consuming harmful weekly amounts of alcohol.
§Adjusted for, sex, and attained age.
kCompared with the British population marriage statistics from ONS 2002.
¶Versus no compared with the general British population.
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